Comparison

Cefpiramide (sodium) European Partner

Item no. HY-B0798-10mM
Manufacturer MedChem Express
CASRN 74849-93-7
Amount 10mM*1 mL
Quantity options 100 mg 10mM*1 mL 10 mg 25 mg 50 mg 5 mg
Category
Type Inhibitors
Clone N/A
Specific against other
Purity 98.47
Citations [1]Barry AL, et al. Cefpiramide: comparative in-vitro activity and beta-lactamase stability. J Antimicrob Chemother. 1985 Sep;16(3):315-25.<br/>[2]Fu KP, et al. Therapeutic efficacy of cefpiramide and cefoperazone alone and in combination with gentamicin against pseudomonal infections in neutropenic mice. Chemotherapy. 1986;32(2):166-72.<br/>[3]Neu HC, et al. The in vitro activity and beta-lactamase stability of cefpiramide compared with other beta-lactam antibiotics. Diagn Microbiol Infect Dis. 1985 Nov;3(6):479-88.
Smiles O=C(C(N12)=C(CSC3=NN=NN3C)CS[C@]2([H])[C@H](NC([C@H](NC(C4=C(O)C=C(C)N=C4)=O)C5=CC=C(O)C=C5)=O)C1=O)O[Na]
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias SM-1652; Wy-44635
Available
Product Description
Cefpiramide sodium (SM-1652; Wy-44635) is a new Pseudomonas-active cephalosporin with a broad spectrum of antibacterial activity. IC50 value: Target: antibacterial agent Cefpiramide was moderately susceptible to hydrolysis by a variety of beta-lactamases from Gram-negative bacilli. cefpiramide was more active against Acinetobacter spp. and Pseudomonas spp. Like most other cephalosporins, cefpiramide inhibited methicillin-susceptible staphylococci, non-enterococcal streptococci, Neisseria gonorrhoeae, N. meningitidis and beta-lactamase-negative Haemophilus influenzae [1]. Pharmacokinetic studies in mice showed that cefpiramide attained a peak serum concentration of 12 micrograms/ml and a serum half-life of 40 min, which are higher than attained by cefoperazone with values of 4 micrograms/ml and 18 min. These factors may have caused the combined cefpiramide-gentamicin therapy to result in significantly improved survival rates in mice as well as in higher bactericidal titers than the cefoperazone-gentamicin combination [2].Cefpiramide inhibited many Pseudomonas aeruginosa resistant to carbenicillin, piperacillin, and cefotaxime, but it was less active than ceftazidime and cefsulodin. Cefpiramide inhibited staphylococci and streptococci and had appreciable activity against Streptococcus faecalis and Listeria moncytogenes [3].
StorageTemperature
4°C (Powder, sealed storage, away from moisture and light)
Shipping
Room Temperature
Manufacturers Applications
COVID-19-immunoregulation
MolecularWeight
634.62
Clinical Information
Launched
Manufacturers Research Area
Infection
Solubility
DMSO : ≥ 39 mg/mL
Target
Antibiotic; Bacterial
Manufacturers Target
Antibiotic; Bacterial
Isoform
β-lactam
Manufacturers Pathway
Anti-infection
Manufacturers Product type
Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 10mM*1 mL
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close